Search

everythinglearnresearchcommunity

for

Search:↓

Research 10 of 1000+

1. JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician Journal of Family Medicine and Primary Care · 2024 · 6 citations
2. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015 · 184 citations
3. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial Journal of the American Academy of Dermatology · 2025 · 2 citations
4. Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus Annals of the rheumatic diseases · 2020 · 16 citations
5. The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells International Journal of Molecular Sciences · 2020 · 16 citations
6. Type-2 immunity associated with type-1 related skin inflammatory diseases: friend or foe? Frontiers in Immunology · 2024
7. Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy JAAD Case Reports · 2023 · 7 citations
8. 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege 2023
9. Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream Pharmaceutics · 2021 · 24 citations
10. 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study Journal of The American Academy of Dermatology · 2021 · 1 citations

Community

— no results